Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acute Lymphoblastic Leukemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    551 result(s) found for: Acute Lymphoblastic Leukemia. Displaying page 1 of 28.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-001739-53 Sponsor Protocol Number: GIMEMA LAL 1004 Start Date*: 2005-03-17
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Therapy with Alemtuzumab (Mabcampath) in patients with acute Lymphoblastic leukemia either refractoy or in relapse. Phase II, multicentric, not randomized study.
    Medical condition: - ALL CD52 positive - Age >18 - Unresponsive to the standard therapy - First or following relapse, also after transplant, and no more eligible to the treatment with other therapies, either conv...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10024290 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002734-41 Sponsor Protocol Number: P091205 Start Date*: Information not available in EudraCT
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001508-38 Sponsor Protocol Number: ST 200-DM-03-005 Start Date*: 2006-03-21
    Sponsor Name:SIGMA-TAU
    Full Title: Phase II Explorative Study of Acetyl-L-Carnitine (ST 200) for Vincristine-Induced Neurotoxicity in Patients With Acute Lymphoblastic Leukemia (ALL).
    Medical condition: Treatment of peripheral sensitive neuropathy vinca alkaloid chemotherapy -induced.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000846 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003466-13 Sponsor Protocol Number: GMALL082013 Start Date*: 2015-09-15
    Sponsor Name:Goethe University Frankfurt
    Full Title: Treatment optimization in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma by individualised, targeted and intensified treatment - a phase IV-trial with a ...
    Medical condition: Newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma Age 18 to 55 y
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000845 Acute lymphoblastic leukemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065923 Lymphoblastic lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018418-53 Sponsor Protocol Number: CSTI571A2110 Start Date*: 2010-06-01
    Sponsor Name:Novartis Pharma Service AG
    Full Title: A non-randomized, open-label study to characterize the pharmacokinetics of Glivec/Gleevec® (imatinib mesylate) in pediatric (age range 1 to less than 4 years) patients with chronic myeloid leukemia...
    Medical condition: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009015 Chronic myeloid leukemia LLT
    12.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) NL (Prematurely Ended) HU (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022036-36 Sponsor Protocol Number: A8641014 Start Date*: 2011-02-15
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 1 trial of pf‑03084014 in patients with advanced solid tumor malignancy and t‑cell acute lymphoblastic leukemia/lymphoblastic lymphoma
    Medical condition: advanced solid tumor malignancies or relapsed or refractory acute T-cell lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066110 LLT
    9.1 10065252 LLT
    9.1 10065923 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-003362-41 Sponsor Protocol Number: Leuk-CTL-001 Start Date*: 2020-09-23
    Sponsor Name:FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO
    Full Title: Phase I/IIa clinical trial on the safety and preliminary efficacy of donor-derived anti-leukemia cytotoxic T lymphocytes for the prevention of leukemia relapse in children given haploidentical hema...
    Medical condition: Leukemia relapse prevention given haploidentical hematopoietic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003624-37 Sponsor Protocol Number: CA180-188 Start Date*: 2007-11-16
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who are Experiencing Clinical Benefit on Current START or CA180039 Protocols: Lon...
    Medical condition: Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009012 Chronic myelogenous leukemia LLT
    9.1 10034877 Philadelphia chromosome positive LLT
    9.1 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) IE (Completed) GB (Completed) IT (Completed) FI (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-006048-15 Sponsor Protocol Number: ALL2820 Start Date*: 2021-05-03
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherap...
    Medical condition: Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000872-14 Sponsor Protocol Number: UCL/11/0519 Start Date*: 2013-07-23
    Sponsor Name:University College London
    Full Title: Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant (ICAT)
    Medical condition: acute myeloid or acute lymphoblastic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000633-17 Sponsor Protocol Number: ALL2922 Start Date*: 2022-08-09
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Combination of Ponatinib Plus Chemotherapy As Frontline Treatment For Patients With BCR/ABL1-Like Acute Lymphoblastic Leukemia (BCR/ABL1-Like ALL) - BALLik
    Medical condition: Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006300-27 Sponsor Protocol Number: MC-ASP.6/INF Start Date*: 2009-08-12
    Sponsor Name:medac Gesellschaft für klinische Spezialpräparate mbH
    Full Title: Efficacy and safety of recombinant asparaginase in infants (< 1 year) with previously untreated acute lymphoblastic leukaemia - Phase II Clinical Trial -
    Medical condition: Acute lymphoblastic leukaemia (ALL) is a clonal disease resulting from genetic mutations and transformation of a single early progenitor lymphoid cell. Uncontrolled expansion of leukaemic blasts in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003912-28 Sponsor Protocol Number: ALL2620 Start Date*: 2021-01-28
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Ponatinib for the management of minimal residual disease (MRD) and hematologic relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients.
    Medical condition: Ph+ Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000758-12 Sponsor Protocol Number: BX-PK-IPC2013-016 Start Date*: 2014-05-30
    Sponsor Name:INSTITUT PAOLI CALMETTES
    Full Title: Study of pharmacokinetics of intravenous busulfan (Busilvex ®) in the conditioning allogeneic transplantation in patients with high-risk hematological disease.
    Medical condition: hematological malignancies : Acute Myeloblastic Leukemia, Chronic Lymphoïd Leukemia, Multiple myéloma, Acute lymphoblastic leukemia.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    17.0 100000004864 10000878 Acute myeloblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002190-28 Sponsor Protocol Number: SHP674-201\CL1-95014-001 Start Date*: 2022-07-04
    Sponsor Name:Institut de Recherches Internationales Servier (IRIS)
    Full Title: A Phase 2 Clinical Study of SHP674 in Patients with Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004577-14 Sponsor Protocol Number: Blina-CELL Start Date*: 2018-12-05
    Sponsor Name:Ústav hematologie a krevní transfuze
    Full Title: Single cycle of blinatumomab followed by high-dose chemotherapy in the induction therapy for Ph-negative acute lymphoblastic leukemia in adults.
    Medical condition: Newly diagnosed, previously untreated, Ph-negative B-precursor acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001172-21 Sponsor Protocol Number: CLO05908 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Japan K.K.
    Full Title: A Phase 1, Open-label, Multi-center Study of Clofarabine in Japanese Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002961-36 Sponsor Protocol Number: EFC11603 Start Date*: 2013-02-11
    Sponsor Name:Sanofi-aventis recherche et développement
    Full Title: Phase II two stage dose finding run-in study of SAR3419, an anti-CD19 antibody-maytansine conjugate,administered as a single agent by intravenous infusion in patients with relapsed or Refractory Ac...
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000846 Acute lymphocytic leukaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004714-25 Sponsor Protocol Number: REALIB-LLA-2017 Start Date*: 2018-07-25
    Sponsor Name:Fundación PETHEMA
    Full Title: Phase I-II trial, open and nonrandomized, to assess the role of Idelalisib in patients with acute lymphoblastic leukemia (ALL) relapsed or refractory to other treatments, and in elderly patients wi...
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000908-18 Sponsor Protocol Number: NOPHO-ALL2008 Start Date*: 2011-06-29
    Sponsor Name:Vilnius University Hospital Santariskiu Clinics
    Full Title: Treatment Protocol for young adults (18-45 years of age) with Acute Lymphoblastic Leukemia
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 05:28:08 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA